hpw - topbar hpw - topbar - diag hpw - topbar xce
 

 Winter 2019 

Subscribe

Forward to a Friend

Share   

    

View Archived Issues

 
IN THIS ISSUE
 
 

We take a closer look at the utilization of multiple criteria decision analysis (MCDA) in health technology appraisals, newer therapies for cystic fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.

 
 
 

 

 

HEARD ON THE STREET
 

"This exciting new international collaboration between two established HTA bodies will help pharmaceutical companies develop relevant evidence for CADTH and NICE while streamlining the process of obtaining advice in two distinct markets."

 
 

— Michelle Mujoomdar, Acting Vice President, Evidence Standards, CADTH
Commenting on the NICE / CADTH collaboration for parallel scientific advice

 

 

 
HTA BY THE NUMBERS
 

$1,000,000

 

The PhRMA Foundation has announced grants totaling $1,000,000 as part of its Value Assessment Initiative. The aim of the initiative is to develop transformative, multi-stakeholder-driven solutions that address challenges in assessing the value of medicines and healthcare services and ultimately improve patient outcomes and reduce inefficiency. The $1,000,000 will be distributed to new centers located at Tufts Medical Center and the University of Colorado.

Tufts' Center for Enhanced Value Assessment (CEVA) will be directed by Peter J. Neumann, ScD. CEVA's mission will include: exploring development of additional value elements; engaging patients and stakeholders to identify important novel and non-standard elements; and reporting findings back to stakeholders.

The University of Colorado's Center for Pharmaceutical Value (PValue), under the direction of Jonathan D. Campbell, PhD, will apply and test novel methods to improve the pharmaceutical coverage and reimbursement decision-making process, with the goal of improving transparency, consistency, and personalization of decisions through multi-criteria decision analysis (MCDA).

     
 
HTA DECISION MAP
 

When HTA Decisions Occur, We Keep You Informed

 
 

Xcenda's HTA Decision Map makes it easy to stay informed. Find out how new products are faring with HTA authorities in:

  • Australia
  • Canada
  • France
  • Germany
  • United Kingdom

 

 

 

 

For more than 2 decades, companies have turned to Xcenda's leading team of value experts, transforming evidence and market intelligence into effective global market access strategies and solutions. Founded in the application of health outcomes and reimbursement, it's our goal to help prove the inherent worth of client products and services, maximize patient access, and enhance overall brand performance.

Explore our solutions >

 

 
 

Subscribe to the newsletter written specifically by and for Global HEOR and Market Access professionals.

 
 
 
EDITORS AND CONTRIBUTING AUTHORS
 

EDITOR-IN-CHIEF:
Kellie Meyer, PharmD, MPH
Vice President,
Global Health Economics & Outcomes Research, Xcenda

MANAGING EDITOR:
Kimberly Riggs, MPH
Director,
Global Health Economics & Outcomes Research, Xcenda

 

EDITORIAL BOARD:

Josep Darba, PhD
Professor | Department of Economics | University of Barcelona

George Papadopoulos, BSc(Hons), GradDipEpi
President | Emerald Corporate Group

Ken Redekop, BSc, MPH, PhD
Associate Professor | Erasmus University Rotterdam

Eldon Spackman, BA, MA, PhD
Co-Director | Institute for Public Health | University of Calgary

Keith Tolley
Director | Tolley Health Economics

Thomas Mittendorf, MSc, PhD
Vice President | Xcenda GmbH

Trent McLaughlin, BSc(Pharm), PhD
Vice President, Real-World Evidence | Xcenda

Michael Eaddy, PharmD, PhD
Vice President, Scientific Consulting | Xcenda

Jay Jackson, PharmD, MPH
Senior Vice President, Consulting Services | Xcenda

CONTRIBUTING AUTHORS:

David Campbell, PharmD, MS | Ryan Clark, PharmD, MBA, MS | Marcus Healey, PhD, MBA, MS | Isabell Kang, PharmD | Kristen Migliaccio- Walle | Linnea Tennant, PharmD, MBA, MS

PRODUCTION:

Laurie Kozbelt | Adam Matheiu | Ellen Olson | Olivia Ziebarth | Elana Gruen
 

 

 

 Winter 2019

Subscribe

Forward to a Friend

Share   

    

View Archived Issues

 
 

Connect with AmerisourceBergen:   AmerisourceBergen.com   I   LinkedIn   I   Twitter   I   AmerisourceBergen Insights

Connect with Xcenda:   Xcenda.com   I   LinkedIn   I  Twitter

 

 

This email was sent on behalf of the sponsor by HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above.
Read more about our privacy policy here. You may also request a copy in writing using the address above.

To ensure you continue to receive emails from HealthEconomics.Com, please click here.